Zhejiang Jingxin Pharmaceutical (SZSE:002020) Jumps 5.8% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Jumps 5.8% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
While Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 24% in the last quarter. Looking further back, the stock has generated good profits over five years. After all, the share price is up a market-beating 30% in that time.
儘管浙江景欣藥業股份有限公司(SZSE:002020)的股東們可能普遍感到高興,但該股最近的表現並不特別好,上個季度股價下跌了24%。再往前看,該股在五年內創造了可觀的利潤。畢竟,在那段時間裏,股價上漲了30%,超過了市場。
The past week has proven to be lucrative for Zhejiang Jingxin Pharmaceutical investors, so let's see if fundamentals drove the company's five-year performance.
事實證明,過去一週對浙江晶欣藥業的投資者來說是有利可圖的,所以讓我們看看基本面是否推動了該公司的五年業績。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
儘管一些人繼續教導高效市場假說,但事實證明,市場是反應過度的動態系統,投資者並不總是理性的。通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。
During five years of share price growth, Zhejiang Jingxin Pharmaceutical achieved compound earnings per share (EPS) growth of 14% per year. This EPS growth is higher than the 5% average annual increase in the share price. So one could conclude that the broader market has become more cautious towards the stock.
在五年的股價增長中,浙江京新藥業實現了每年14%的複合每股收益(EPS)增長。每股收益的增長高於股價每年平均增長5%。因此,人們可以得出結論,整個市場對該股變得更加謹慎。
The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).
下圖描述了 EPS 隨着時間的推移是如何變化的(點擊圖片可以看到確切的值)。
Dive deeper into Zhejiang Jingxin Pharmaceutical's key metrics by checking this interactive graph of Zhejiang Jingxin Pharmaceutical's earnings, revenue and cash flow.
查看這張浙江景新藥業收益、收入和現金流的互動圖表,深入了解浙江景新藥業的關鍵指標。
What About Dividends?
分紅呢?
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for Zhejiang Jingxin Pharmaceutical the TSR over the last 5 years was 50%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!
在考慮投資回報時,重要的是要考慮兩者之間的區別 股東總回報 (TSR) 和 股價回報。基於股息再投資的假設,股東總回報率納入了任何分拆或貼現資本籌集的價值以及任何股息。可以公平地說,股東總回報率爲支付股息的股票提供了更完整的畫面。我們注意到,對於浙江景新藥業而言,過去5年的股東總回報率爲50%,好於上述股價回報率。這在很大程度上是其股息支付的結果!
A Different Perspective
不同的視角
The total return of 17% received by Zhejiang Jingxin Pharmaceutical shareholders over the last year isn't far from the market return of -17%. Longer term investors wouldn't be so upset, since they would have made 8%, each year, over five years. If the fundamental data remains strong, and the share price is simply down on sentiment, then this could be an opportunity worth investigating. It's always interesting to track share price performance over the longer term. But to understand Zhejiang Jingxin Pharmaceutical better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Zhejiang Jingxin Pharmaceutical you should know about.
去年,浙江景欣藥業股東獲得的17%的總回報率與-17%的市場回報率相差不遠。長期投資者不會那麼沮喪,因爲他們本可以在五年內每年賺8%。如果基本面數據保持強勁,而股價僅因市場情緒而下跌,那麼這可能是一個值得研究的機會。長期跟蹤股價表現總是很有意思的。但是,要更好地了解浙江晶欣藥業,我們需要考慮許多其他因素。例如,考慮風險。每家公司都有它們,我們已經發現了兩個你應該知道的浙江景新藥業的警告標誌。
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。